Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approval of SPN-830, an apomorphine infusion device, as a new treatment for OFF episodes in patients with Parkinson disease (PD). Marketed under the name ___, the medication is designed as an under-the-skin continuous infusion therapy used between doses of standard levodopa-based therapy. Its approval was based on the phase 3 TOLEDO study (NCT02006121), a multicenter trial that showed that treatment with SPN-830 resulted in –1.89 hours per day of better OFF time than placebo, with reductions observed within 1 week of initiating therapy. To provide insight on how this therapy will impact patients with PD, Stuart Isaacson, MD, a PD and movement disorders specialist who serves as the Medical Director of the Parkinson’s Research & Education Foundation at the Institute for Neurodegenerative Diseases of Florida. Isaacson sat down for a few minutes to discuss some of the notable aspects to this therapy, how it will be used in clinical practice, and the safety and efficacy during its approval process. 

For more of NeurologyLive's coverage of SPN-830's approval, head here: 

Episode Breakdown:

0:30 – 

2:00 – 

3:35 – 

4:50 –

5:40 – 

6:45 – 

8:55 – 

10:15 – 

Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.